Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Veradermics stock (MANE) sits at $118.87, up 1.81% today. The business is worth $4.97B in the market, good for #2116 of 3132 on our coverage list.
The 52-week range is $32.00 to $131.24. Today's price is about 88% of the way from the low to the high.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
MANE is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
Quote as of Oct 5, 2026 10:20 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,132 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$118.87 is the latest print for MANE, a move of +1.81% against yesterday's close of $116.76. Today's low and high so far: $114.80 and $119.12.
Equity value comes to $4.97B at the current price. By that measure it is number 2116 of the 3132 names in our coverage.
The year's floor is $32.00 and the ceiling $131.24. Shares are 9.4% away from that ceiling.
Our data shows no dividend paid by Veradermics over the trailing twelve months.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on MANE.